Skip to content
Review Open access

Immunometabolic Regulation of Macrophage Function in Cardio-Hepatic-Renal Comorbidities: Mechanisms and Therapeutic Opportunities.

Sep 2026 · Molecular and Cellular Endocrinology · pp. 112918 · 0 citations · 45 references
Medicine

TL;DR

This study systematically summarize the roles of macrophage polarization, phenotypic remodeling and metabolic activation in the injury of three metabolic organs, and analyzes their mediating functions in inter-organ immune-metabolic crosstalk and the associated pathological connections.

Abstract

This review examines metabolic comorbidities affecting the heart, liver and kidney. The clinical prevalence of cardiohepatorenal metabolic comorbidities associated with obesity and type 2 diabetes is substantial. Chronic low-grade inflammation serves as the fundamental pathogenic mechanism. Abnormal macrophage activation is associated with metabolic disorders and damage to multiple organs. The conventional M1/M2 binary classification fails to adequately capture the heterogeneity of macrophages in vivo. Previous studies have primarily focused on the investigation of individual organs, leaving the cross-organ immune-metabolic linkage mechanism poorly understood. Furthermore, targeted interventions often lack precision. In this study, we systematically summarize the roles of macrophage polarization, phenotypic remodeling and metabolic activation in the injury of three metabolic organs. We also analyze their mediating functions in inter-organ immune-metabolic crosstalk and the associated pathological connections. Glycolipid toxicity impairs the glycolipid metabolism of macrophages via the NLRP3/SIRT pathway, resulting in a pro-inflammatory polarization advantage. Specific subsets of macrophages, including CCR2+,TREM2+,and CD206+CD68+,are involved in mediating myocardial remodeling, liver fibrosis, and renal interstitial injury, respectively.Medications such as SGLT2 inhibitors and GLP-1 receptor agonists may provide multi-organ protection by modulating macrophage activity. The current research presents several limitations, including species differences between humans and mice, ambiguous temporal transformation rules of macrophages, and inadequate specificity of targeted preparations.Future efforts should leverage spatial multi-omics and gene editing technologies to analyze the global regulatory network and develop highly selective targeted strategies. This approach can offer theoretical support for the integrated and precise prevention and management of metabolic comorbidities.

Read PDF

Similar papers

Review Open access Sep 2026

Roles of inflammation and metabolic dysfunction in cardiovascular diseases: molecular mechanisms and therapeutic targets

Cardiovascular disease progression is shaped by a close interaction between metabolic adaptation and inflammatory signaling. In injured cardiac and vascular tissues, ischemia, pressure overload, lipid stress and metabolic excess reshape how cardiomyocytes, endothelial cells, immune cells and fibroblasts sense damage an...

Yue Pan, Wan-Hong Li, Wei Zhang et al. · 0 citations
Review Sep 2026

Immunometabolic Pathways in Hepatotoxicity: Cross-Talk Between the Liver and Peripheral Immune Cells

Hepatotoxicity arises from a complex interplay of metabolic dysregulation, immune activation, and inflammatory signaling within the liver and beyond. The liver is not only the primary organ for xenobiotic metabolism but also a central immunological hub that constantly interacts with peripheral immune cells through cyto...

Kungu Erisa · 0 citations
Review Open access Sep 2026

Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential

This review comprehensively elucidates the pathophysiological mechanisms and translational potential of immune checkpoint regulation in obesity, diabetes, and thyroid disease while proposing novel directions for clinical intervention.

Min-Min Xiang, Shuang Liu, De-Sheng Xiao et al. · 1 citation
Review Open access Sep 2026

Immune metabolic reprogramming in MASLD.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge driven by the interplay between metabolic dysregulation and chronic low-grade inflammation. Beyond simple hepatic lipid accumulation, MASLD is characterized by extensive remodeling of the liver immune microenvironment in...

Joanna Razafiarison, Nicolas Venteclef, Florent Ginhoux et al. · 0 citations
Review Open access Oct 2026

Liver X receptor (LXR) signaling in macrophage inflammation and cardiometabolic disease.

Cardiometabolic diseases profoundly remodel tissue immune landscapes, characterized by the accumulation of diverse macrophage subtypes. Among these, lipid-associated macrophages (LAMs) have emerged as an important subset that is frequently observed in cardiometabolically affected tissues. LAMs are defined by a transcri...

L. Zijlstra, M. de Winther, S. Kooijman et al. · 0 citations
Review Open access Sep 2026

Multidimensional regulation of hepatic macrophages in chronic liver disease: from metabolic reprogramming to intercellular and interorgan crosstalk

Chronic liver diseases (CLDs), including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD, viral hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)), impose enormous global public health burdens. Hepatic macrophages act as core orchestrators go...

Cheng-Hao Xu, Xin-Yu Zhu, Hai-Na Xie et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.